NYSE:WAT - Waters Stock Price, News, & Analysis

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Waters announced that its Board of Directors has approved a stock repurchase plan on Tuesday, April 24th 2018, which allows the company to buyback $3,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 18.2% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

Waters Co. (NYSE:WAT) issued its quarterly earnings results on Tuesday, July, 24th. The medical instruments supplier reported $1.95 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.92 by $0.03. The medical instruments supplier had revenue of $596.20 million for the quarter, compared to analysts' expectations of $598.73 million. Waters had a net margin of 2.12% and a return on equity of 27.85%. The firm's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the prior year, the company earned $1.76 earnings per share. View Waters' Earnings History.

Waters is scheduled to release their next quarterly earnings announcement on Tuesday, October, 23rd 2018. View Earnings Estimates for Waters.

Waters updated its FY18 earnings guidance on Tuesday, July, 24th. The company provided EPS guidance of $8.05-8.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.18. Waters also updated its Q3 guidance to $1.85-1.95 EPS.

16 equities research analysts have issued 12-month price objectives for Waters' stock. Their forecasts range from $180.00 to $230.00. On average, they anticipate Waters' stock price to reach $205.50 in the next year. This suggests a possible upside of 9.6% from the stock's current price. View Analyst Price Targets for Waters.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Waters.

Some companies that are related to Waters include Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories, Inc. Class B (BIO.B), PerkinElmer (PKI), Bio-Rad Laboratories, Inc. Class A Common Stock (BIO), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO) and Eyepoint Pharmaceuticals (EYPT).

News articles about WAT stock have trended somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Waters earned a news impact score of 0.20 on Accern's scale. They also gave media headlines about the medical instruments supplier an impact score of 47.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for Waters.

Waters' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.30%), Massachusetts Financial Services Co. MA (6.09%), Fundsmith Equity Fund L.P. (6.14%), Bank of New York Mellon Corp (5.56%), Baillie Gifford & Co. (3.26%) and Janus Henderson Group PLC (2.67%). Company insiders that own Waters stock include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Ian King, Joann A Reed, Laurie H MD Glimcher, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Michael J Berendt, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Institutional Ownership Trends for Waters.

WAT stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, Veritas Asset Management LLP, Massachusetts Financial Services Co. MA, Renaissance Technologies LLC, American Century Companies Inc., Millennium Management LLC and Russell Investments Group Ltd.. Company insiders that have sold Waters company stock in the last year include Christopher A Kuebler, David Terricciano, Elizabeth B Rae, Eugene G Cassis, Joann A Reed, Mark T Beaudouin, Michael C Harrington, Michael F Silveira, Rohit Khanna, Terrence P Kelly, Thomas P Salice and William J Miller. View Insider Buying and Selling for Waters.

WAT stock was bought by a variety of institutional investors in the last quarter, including Fundsmith Equity Fund L.P., Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, Assenagon Asset Management S.A., Schroder Investment Management Group, Select Equity Group L.P. and Mawer Investment Management Ltd.. View Insider Buying and Selling for Waters.

Shares of WAT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WAT stock can currently be purchased for approximately $187.43.

Waters has a market capitalization of $14.45 billion and generates $2.31 billion in revenue each year. The medical instruments supplier earns $20.31 million in net income (profit) each year or $7.49 on an earnings per share basis. Waters employs 7,000 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The medical instruments supplier can be reached via phone at 508-478-2000 or via email at [email protected]